Universität zu Köln

Sasse, S., Momotow, J. and Engert, A. (2020). Checkpoint inhibitors in Hodgkin lymphoma. Internist, 61 (7). S. 660 - 669. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1289

Full text not available from this repository.

Abstract

Background Checkpoint blockade contributes to the immunosuppressive microenvironment in classical Hodgkin lymphoma (cHL) and in particular the interaction of Hodgkin cells and macrophages with T-cells and natural killer cells via programmed cell death 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1). Objectives The aim of this article is the evaluation the role and potential of checkpoint blockade in cHL as compared with the results of standard chemo- and radiotherapy. Methods We analyzed preclinical and clinical data from phase I and phase II studies with checkpoint blockade in cHL. Results and discussion In 60-70% of patients with chemotherapy-refractory cHL, PD-1 blockade results in responses. Overall survival is excellent and a small number of patients achieve persistent response. Thus, the use of anti-PD-1 monoclonal antibodies has become an important treatment approach in relapsed cHL in line with the label. The results of first-line therapy are still preliminary; initial phase II studies using nivolumab in combination with doxorubicin (=adriamycin), vinblastin and dacarbazin (AVD) in early unfavorable or advanced stages showed response rates of up to 90%. Thus, implementing immunomodulatory approaches using PD 1-blockade have resulted in a significant reduction of chemotherapy. This might represent a paradigm shift in the therapy of cHL.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sasse, S. UNSPECIFIED UNSPECIFIED UNSPECIFIED Momotow, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-328419
DOI:	10.1007/s00108-020-00811-2
Journal or Publication Title:	Internist
Volume:	61
Number:	7
Page Range:	S. 660 - 669
Date:	2020
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1432-1289
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; BRENTUXIMAB VEDOTIN; FOLLOW-UP; IMMUNE EVASION; PHASE-II; NIVOLUMAB; SINGLE; TRIAL; PEMBROLIZUMAB; MULTICOHORT Multiple languages Medicine, General & Internal Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/32841